Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2022-08-01 00:00:00 ET · period of report 2022-07-28 · accession 0000899243-22-027169 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-08-01 | 2022-07-28 | KLRS | ElevateBio, LLC | Dir, 10% | A - Grant | $4.61 | +3.25M | 16.67M | +24% | +$15.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-07-28 | A | A | 3,253,796 | $4.61 | 16,674,766 | D | — | — | (F2) These shares are directly held by ElevateBio. David Hallal, Vikas Sinha, Morana Jovan-Embiricos and Ansbert Gadicke are directors of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. Such persons disclaim beneficial ownership of all shares held by ElevateBio except to the extent of their pecuniary interest therein, if any. |